Pasireotide: potential treatment option for McCune–Albright-associated acromegaly
Authors' conclusion
Thus, pasireotide LAR is clearly useful as third-line therapy, and potentially even as second-line therapy, in MAS-associated acromegaly.
Study context
- Population
- Patients with McCune-Albright syndrome (MAS)-associated acromegaly treated with pasireotide long-acting release (LAR) in one center
- Participants
- 3 patients
- Outcome
- IGF-I normalization
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Pasireotide LAR 20 mg/month: rapid and long-term IGF-I normalization in patients #1 (also controlled on first-generation somatostatin receptor ligands (fg-SRLs)) and #3 (fg-SRL resistant)
- Patient #2 (fg-SRL resistant, uncontrolled on pegvisomant 40 mg/day + cabergoline 0.5 mg/day): pegvisomant replaced with pasireotide LAR 40 mg/month, near normalization of IGF-I
Observational data: associations, not effects.
Safety
- Patients developing intermittent impaired fasting glucose, without need for glucose-lowering drugs
- 3
Original publication
Pasireotide: potential treatment option for McCune–Albright-associated acromegaly. Eur J Endocrinol. Published 21 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →